Swedish researchers discover a blood test that can detect Parkinson's disease up to 20 years before symptoms appear, offering ...
More than 1.1 million Americans live with the degenerative brain condition, which can trigger debilitating tremors and effect memory ...
Peer-reviewed Phase 2 Results Inform Ongoing Phase 3/Pivotal Trial of Celeste® in Parkinson’s Disease The Phase 2 study ...
A team led by researchers at Chalmers University of Technology, Sweden, has succeeded in identifying biomarkers for Parkinson ...
New research reveals how Parkinson's spreads from the gut to the brain, with the help of immune cells—offering a new ...
TRPML1 is a promising target1 for Parkinson’s disease treatments and identifying translational biomarkers will help confirm target engagement ...
ABLi Therapeutics ("ABLi"), a biotechnology company developing therapeutics to address diseases that are associated with activation of Abelson Tyrosine Kinases (c-Abl kinases), announces it has ...
Annovis is also seeking fresh capital while working to advance trials for both Alzheimer's and Parkinson's disease drugs.
ClearPoint Neuro is positioned for robust growth in 2026, driven by IRRAS, the PRISM 1.5T system clearance, and the company's new CRO facility. While the immediate future of uniQure's AMT-130 remains ...
The first good manufacturing practices facility located on a university campus in the United States opened this fall at the ...
Insilico Medicine (3696.HK), a clinical-stage drug discovery and development company driven by generative artificial ...
SPARK NS and Haukeland University Hospital today announced they are collaborating on a randomized, double-blind, placebo-controlled, Phase 2b study to evaluate the efficacy of orally administered ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results